biostudies-literatureUnknown7(45)Perrone F<h4>Background</h4>No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC.<h4>Patients and methods</h4>MITO2 is a randomised multicentre phase 3 trial conducted with 820 AOC patients assigned carboplatin/paclitaxel (carboplatin: AUC5, paclitaxel: 175 mg/m², every 3 weeks for 6 cycles) or carboplatin/PLD-pegylated liposomal doxorubicin (carboplatin: AUC5, PLD: 30 mg/m², every 3 weeks for 6 cycles) as first line treatment. Sixteen biomarkers (pathways of adhesion/invasion, apoptosis, transcription regulation, metabolism, and DNA repair) were studied in 229 patients, in a tissue microarray. Progression-free and oveOncotarget72654-72661https://www.ebi.ac.uk/biostudies/studies/S-EPMC5341934biostudies-literatureBiomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.PMC5341934Perrone FSonego MChiappetta GSorio RZannoni GFZulato ESignoriello SNatale DLosito SScambia GBaldassarre GFebbraro AEsposito FFerro AScollo PScognamiglio GGallo CDi Maio MCanzonieri VTamberi SPignata SLorusso DIndraccolo SFranco RSavarese ACanevari SFerrandina GMezzanzanica DBreda ECalifano DfalseBiomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.<h4>Background</h4>No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC.<h4>Patients and methods</h4>MITO2 is a randomised multicentre phase 3 trial conducted with 820 AOC patients assigned carboplatin/paclitaxel (carboplatin: AUC5, paclitaxel: 175 mg/m², every 3 weeks for 6 cycles) or carboplatin/PLD-pegylated liposomal doxorubicin (carboplatin: AUC5, PLD: 30 mg/m², every 3 weeks for 6 cycles) as first line treatment. Sixteen biomarkers (pathways of adhesion/invasion, apoptosis, transcription regulation, metabolism, and DNA repair) were studied in 229 patients, in a tissue microarray. Progression-free and ove2016-01-01T00:00:00Z2016 Nov2026-05-30T05:39:43.085Z2019-03-27T02:38:07ZS-EPMC53419342765564310.18632/oncotarget.12056